GDC-1261 and INR731 enter phase 1, but how do they act?
ApexOnco Front Page
Recent articles
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
A fresh licensing deal tidies up years of work between the two companies.
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
And that could affect the drug's third-line accelerated approval.
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
